Oncological Diseases Screening And NLS-technologies With Metatron Hunter 4025

Oncological diseases screening. Screening as an organized measure is aimed towards person’s disease exposure who have no clinical signs of the disease itself and who have no reasons to seek medical care.  Mass NLS-research activities with the purpose of oncological diseases early diagnosis always had a number of supporters and opponents. It is caused by the fact that exposure of tumor in preclinical stage does not always correspond to the term “early diagnosis”. In the present days there are some stated basic requirements to every oncological screening program, including the ones based on NLS-technologies with metatron hunter 4025;  The disease must be enough-spread and have high social implication;  NLS-diagnosis method is essential to expose the disease in preclinical stage;   There should be an opportunity to cure an exposed disease with the help of existing techniques;    Screening should bring to decrease death-rate caused by stated disease in population;  Screening should be economically sound i.e. the outlays for early diagnosis should be lower than patients treatment costs, who sought medical care with clinical symptoms.

The effectiveness of oncological diseases screening nowadays cannot be doubted. During the last years main discussions about these programs individual aspects were spread, in particular:  ü

Age limits, when it is appropriate to start and finish screening procedures, its dependence upon national peculiarities; ü

The possibility of NLS use for cancer of various localization evaluation; ü  

The status of technology in primary and qualifying oncological diseases diagnosis.

There are other pre-clinical diagnostics programs that develop intensely, such as early cancer of lung exposure using virtual multivariate NLS-scopy, large intestine cancer based upon virtual multivariate NLS-scopy in combination with CT or MR – colonoscopy. Among them the most important results are received in the cancer of lung case study early-diagnosis.  

Modern perspective diagnosis programs for studying the possibilities of bronchogenic cancer screening are based on virtual spiral NLS using. In comparison with rontgenography and fluorography the main advantage of this technology is fundamentally high resolution. Using virtual NLS allows effective exposure of nidi in lung tissue sizing 0,5-0,7 mm. In most of major researches it is shown that virtual NLS allows revealing lung nidi of 10-12% patients from high-risk group, where 0,5-1,5% are bronchogenic cancer. More than 80% of these tumors are not seen while rontgenography, resolution limit of which is 3-5mm. NLS can expose cancer at first stage of 80-95% of patients.  

The main limitations for virtual NLS-scopy of bronchogenic cancer screening wide application are high number of false-positive results, the lack of conclusive proofs in decreasing of patients death rate in screening groups compared with other groups or population as a whole.